Skip to main navigation Skip to search Skip to main content

Nanomedicine platform for targeting activated neutrophils and neutrophil-platelet complexes using an α1-antitrypsin-derived peptide motif

  • Michelle A Cruz
  • , Dillon Bohinc
  • , Elizabeth A Andraska
  • , Jurgis Alvikas
  • , Shruti Raghunathan
  • , Nicole A Masters
  • , Nadine D van Kleef
  • , Kara L Bane
  • , Kathryn Hart
  • , Kathryn Medrow
  • , Michael Sun
  • , Haitao Liu
  • , Shannon Haldeman
  • , Ankush Banerjee
  • , Emma M Lessieur
  • , Kara Hageman
  • , Agharnan Gandhi
  • , Maria de la Fuente
  • , Marvin T Nieman
  • , Timothy S Kern
  • Coen Maas, Steven de Maat, Keith B Neeves, Matthew D Neal, Anirban Sen Gupta, Evi X Stavrou

Research output: Contribution to journalArticleAcademicpeer-review

1 Downloads (Pure)

Abstract

Targeted drug delivery to disease-associated activated neutrophils can provide novel therapeutic opportunities while avoiding systemic effects on immune functions. We created a nanomedicine platform that uniquely utilizes an α 1-antitrypsin-derived peptide to confer binding specificity to neutrophil elastase on activated neutrophils. Surface decoration with this peptide enabled specific anchorage of nanoparticles to activated neutrophils and platelet-neutrophil aggregates, in vitro and in vivo. Nanoparticle delivery of a model drug, hydroxychloroquine, demonstrated significant reduction of neutrophil activities in vitro and a therapeutic effect on murine venous thrombosis in vivo. This innovative approach of cell-specific and activation-state-specific targeting can be applied to several neutrophil-driven pathologies.

Original languageEnglish
Pages (from-to)1004-1014
Number of pages11
JournalNature nanotechnology
Volume17
Issue number9
DOIs
Publication statusPublished - Sept 2022

Keywords

  • Animals
  • Humans
  • Hydroxychloroquine/pharmacology
  • Leukocyte Elastase/metabolism
  • Mice
  • Nanomedicine
  • Neutrophils
  • alpha 1-Antitrypsin Deficiency

Fingerprint

Dive into the research topics of 'Nanomedicine platform for targeting activated neutrophils and neutrophil-platelet complexes using an α1-antitrypsin-derived peptide motif'. Together they form a unique fingerprint.

Cite this